Literature DB >> 27507767

Childhood-Diagnosed ADHD, Symptom Progression, and Reversal Learning in Adulthood.

Hazel McCarthy1, Jessica Stanley1, Richard Piech2, Norbert Skokauskas1,3, Aisling Mulligan4,5, Gary Donohoe1, Diane Mullins1, John Kelly1, Katherine Johnson1,6, Andrew Fagan1,7, Michael Gill1,7, James Meaney7, Thomas Frodl1,8.   

Abstract

OBJECTIVE: ADHD persists in up to 60% into adulthood, and the reasons for persistence are not fully understood. The objective of this study was to characterize the neurofunctional basis of decision making in those with a childhood diagnosis of ADHD with either persistent or remitted symptoms in adulthood versus healthy control participants.
METHOD: Thirty-two adults diagnosed with ADHD as children were split into persistent ( n = 18) or remitted ( n = 14) ADHD groups. Their neural activity and neurofunctional connectivity during a probabilistic reversal learning task were compared with 32 healthy controls.
RESULTS: Remitters showed significantly higher neural connectivity in final reversal error and probabilistic error conditions, and persisters depict higher neural connectivity in reversal errors than controls at a family-wise error (FWE) corrected whole-brain corrected threshold.
CONCLUSION: Remitters may have utilized higher neural connectivity than controls to make successful decisions. Also, remitters may have utilized compensatory strategies to override any potential underlying ADHD deficits.

Entities:  

Keywords:  ADHD; functional neuroimaging; persistence; remission

Mesh:

Year:  2016        PMID: 27507767     DOI: 10.1177/1087054716661233

Source DB:  PubMed          Journal:  J Atten Disord        ISSN: 1087-0547            Impact factor:   3.256


  1 in total

1.  Neural Correlates of Working Memory Deficits in Different Adult Outcomes of ADHD: An Event-Related Potential Study.

Authors:  Xixi Zhao; Hui Li; Encong Wang; Xiangsheng Luo; Chuanliang Han; Qingjiu Cao; Lu Liu; Jin Chen; Changming Wang; Stuart J Johnstone; Yufeng Wang; Li Sun
Journal:  Front Psychiatry       Date:  2020-05-01       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.